美国Advanced Cell Technology, Inc.
美国先进细胞技术公司，设在美国马萨诸塞州伍斯特。 该公司首次利用克隆技术培育出人类早期胚胎。
是体细胞克隆、治疗性克隆和胚胎干细胞、转基因畜牧动物生物反应器等科技研发和产业化领域中的世界领导者。
ACT的体细胞克隆、胚胎干细胞和转基因及基因工程这三大技术支柱，是农业中畜牧业变革性发展的新动力，是医学领域内实现再生治疗性自体细胞、组织、器官和生物制药等治疗手段革命性创新的重要基础，是再生医学产业到来的驱动器。

Advanced Cell Technology, Inc. (OTCBB:ACTC – News) is applying stem cell technology in the field of regenerative medicine to bring effective, patient-specific therapies to the bedside. The company’s Myoblast program is an autologous adult stem cell therapy for the treatment of heart disease. The Myoblast program has successfully completed four Phase I clinical trials and has clearance from the FDA to begin Phase II trials shortly. The company is also rapidly moving towards human clinical trials for its embryonic stem cell therapies including its RPE and HG programs. ACT published positive data from animal studies for its RPE (retinal pigment epithelial) cell program for the treatment of retinal degenerative disorders completed in collaboration with the Casey Eye Institute at Oregon Health and Science University. The company also has GLP Safety Studies in process for its RPE Program. ACT published positive data in the journal NATURE Methods for its HG (hemangioblast) cell program for the treatment of blood and cardiovascular diseases. The company expects to file INDs for its RPE and HG programs in 2008. In August 2006, ACT announced a novel technique to generate embryonic stem cell lines without destroying embryos, a breakthrough in the ethical debate surrounding the industry. Since then, the company has announced on multiple occassions the creation of human embryonic stem cell lines without destroying the developmental potential of the embryos. ACT owns or licenses over 380 patents and patent applications.